Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WHO grants emergency use listing for Moderna’s Covid-19 vaccine
World Health Organization (WHO) has granted emergency use listing (EUL) for Moderna’s Covid-19 vaccine to prevent the infection in people aged 18 years and above. The Covid-19 Vaccine
World Health Organization (WHO) has granted emergency use listing (EUL) for Moderna’s Covid-19 vaccine to prevent the infection in people aged 18 years and above. The Covid-19 Vaccine
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China. Maralixibat is a minimally absorbed, orally
Pharmaceutical company Pfizer has acquired a privately held company Amplyx Pharmaceuticals for an undisclosed amount. Amplyx is developing treatment for life-threatening diseases caused due to failing immune system.
Merck, called as MSD outside the US and Canada, has signed voluntary licensing agreements with five Indian generic drug makers to expand access to Molnupiravir, an experimental oral
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorisation for AstraZeneca and Merck’s selumetinib to treat paediatric patients aged
A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells
Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing. The strategic collaboration and research and licensing agreement
Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107. The clinical study is to evaluate the pharmacokinetics and
Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile
The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC). This second approval of Sarclisa